Saracatinib in Treating Patients With Metastatic or Locally Advanced Breast Cancer That Cannot Be Removed By Surgery

Inclusion Criteria:

* Histologically or cytologically confirmed carcinoma of the breast

  * Unresectable disease
  * Locally advanced or metastatic (American Joint Committee on Cancer \[AJCC\] stage IV) disease
* Estrogen receptor-negative and progesterone receptor-negative breast cancer defined as \< 10% expression by immunohistochemistry (IHC)
* Measurable disease, defined (per Response Evaluation Criteria in Solid Tumors \[RECIST\]) as ≥ 1 unidimensionally measurable lesion ≥ 20mm by conventional techniques or ≥ 10 mm by spiral computed tomography (CT) scan

  * Measurable target lesions must not be in a previously irradiated field
* Patients with locally advanced, unresectable disease must have progression of disease following no more than one first-line chemotherapy regimen
* Patients with evidence of recurrent disease during or within 6 months after adjuvant chemotherapy will be considered to have failed one line of chemotherapy for metastatic disease
* Human epidermal growth factor receptor 2 (HER2)-positive patients, defined as immunohistochemistry (IHC) 3+ or fluorescence in situ hybridization (FISH) amplification \> 2.1, must have received trastuzumab (Herceptin®) in either the adjuvant or metastatic setting and have had recurrence or progression of disease, respectively
* No known brain metastases
* Male and female patients eligible
* Menopausal status not specified
* Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤ 2 (Karnofsky PS 60-100%)
* Life expectancy \> 3 months
* Absolute neutrophil count ≥ 1,500/mcL
* Platelet count ≥ 100,000/mcL
* Hemoglobin \> 9 g/dL
* Total bilirubin normal
* Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase \[SGOT\])/alanine aminotransferase (ALT) (serum glutamic pyruvate transaminase \[SGPT\]) ≤ 2.5 x institutional upper limit of normal
* Creatinine normal OR creatinine clearance ≥ 60 mL/min
* Urine protein creatinine (UPC) ratio must be ≤ 1.0

  * Patients with a UPC ratio \> 1.0 must have a 24-hour urine protein \< 1,000 mg to be eligible for study
* Not pregnant or nursing
* Women of child-bearing potential and men must use adequate contraception (e.g., hormonal or barrier method of birth control or abstinence) prior to, during, and for 8 weeks after completion of study therapy
* Able to understand and willing to sign a written informed consent document
* No history of allergic reactions attributed to compounds of similar chemical or biological composition to AZD0530
* No QTc interval ≥ 500 msecs
* No condition that impairs the ability to swallow AZD0530 tablets, including the following:

  * Gastrointestinal tract disease resulting in an inability to take oral medication or a requirement for IV alimentation
  * Prior surgical procedures affecting absorption
  * Active peptic ulcer disease
* No intercurrent cardiac dysfunction including, but not limited to, any of the following:

  * Symptomatic congestive heart failure
  * Unstable angina pectoris
  * Uncontrolled cardiac arrhythmia
  * History of myocardial infarction within 6 months of treatment
* No uncontrolled intercurrent illness including, but not limited to, ongoing or active infection or psychiatric illness/social situations that would limit compliance with study requirements
* No severe restrictive or obstructive lung disease according to baseline pulmonary function studies including any of the following pulmonary function test (PFT) parameters:

  * Total lung capacity \< 60%
  * Forced vital capacity \< 50%
  * Forced expiratory volume in one second (FEV\_1) \< 50%
  * Diffusion capacity of carbon monoxide (DLCO) \< 50%
  * Resting room air O\_2 saturation \< 92% or a decline in O\_2 saturation \> 4% with exercise
* Patients with metastatic disease may have received no more than 1 prior chemotherapy regimen
* No unresolved toxicity ≥ grade 3 from agents received more than 3 weeks earlier
* No chemotherapy, radiotherapy, or investigational therapy within 3 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering study
* No luteinizing hormone-releasing hormone agonists within 4 weeks prior to study entry
* More than 7 days since prior and no concurrent use of specifically prohibited cytochrome P 450 3A4 (CYP3A4) agents
* No concurrent megestrol acetate, even when prescribed for appetite stimulation
* No other concurrent investigational or commercial agents for the treatment of breast cancer
* No concurrent combination antiretroviral therapy for human immunodeficiency virus (HIV)-positive patients
* No concurrent megestrol acetate